Palacios · Brain research 2016 · Historical review and preclinical autoradiographic mapping study · n=?

Serotonin receptors in brain revisited.

Cited 65 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical rodent tissue mapping and narrative historical review (Level 5 by design analogy).

PubMed 26740406 · doi:10.1016/j.brainres.2015.12.042 · record verified 2026-08-26

What was done

The authors reviewed the historical discovery of serotonin receptor diversity and presented quantitative light microscopic autoradiographic mapping of 5-HT1 receptor subtypes (5-HT1A, 5-HT1B, 5-HT1C) in rat brain sections. Receptors were labeled using radioligands ([(3)H]serotonin, 8-OH-[(3)H]DPAT, [(3)H]LSD, and [(3)H]mesulergine) alongside competition assays with subtype-selective agonists, and regional densities were quantified with computer-assisted microdensitometry.

What was found

[(3)H]serotonin labeled all 5-HT1 subtypes with nanomolar affinity, while 8-OH-[(3)H]DPAT selectively labeled 5-HT1A, [(3)H]mesulergine labeled 5-HT1C, and [(3)H]LSD labeled both. Specific subtypes mapped to distinct anatomical structures: - Choroid plexus exhibited the highest overall receptor concentration, predominantly 5-HT1C. - Dentate gyrus and lateral septal nucleus were enriched in 5-HT1A sites. - Globus pallidus, ventral pallidum, dorsal subiculum, substantia nigra, and olivary pretectal nucleus were enriched in 5-HT1B sites. - Hippocampal fields CA1-CA4, amygdaloid nuclei, hypothalamic nuclei, and dorsal raphe had high concentrations. - Claustrum, olfactory tubercle, nucleus accumbens, central gray, and lateral cerebellar nucleus showed intermediate densities. - Caudate-putamen and cerebral cortex showed intermediate to low densities, while the pons, medulla, and spinal cord had low or very low densities. Exact quantitative receptor density values (such as fmol/mg tissue) were not reported in the abstract.

Why it matters

The mapping demonstrated that distinct serotonin receptor subtypes are expressed by different neuronal populations across specific brain circuits, validating pharmacological subtype classifications prior to molecular cloning.

Limits

The data are derived from ex vivo rodent brain tissue and do not assess human neuroanatomy, in vivo functional signaling, or behavioral outcomes. The abstract does not report the number of animal subjects (n) or exact numerical binding densities and affinity constants.

Cited by